Table 1 Characteristics of the studies included in the meta-analysis
Study | Design | Follow up (months) | Age (years) | plus power | Subjects (E/C) | Treatment lens | Baseline refraction(D) | Treatment effect | |
|---|---|---|---|---|---|---|---|---|---|
Axial length | Myopia control | ||||||||
Cheng USA, 2019 | RCT | 12 | 8–11 | + 0.175 μm | 53/59 | Positive spherical aberration | -2.25 ± 1.09 | 37% | 18% |
Fujikado Japan,2014 | RCT | 12 | 10–16 | + 0.50D | 24/24 | Menicon low-addition | −0.75 ∼ − 3.50 | 47% | 26% |
Sankaridurg China, 2019 | RCT | 24 | 8–13 | + 1.50D | 101/102 | Progressive periphery | −0.75 ∼ − 3.50 | 23% | 21% |
Walline USA, 2020 | RCT | 24 | 7–11 | + 2.50D | 97/97 | multifocal soft lenses | −1.00 ∼ − 6.00 | 36% | 43% |
Garcia-del Valle Spain,2020 | RCT | 12 | 7–15 | + 2.00D | 36/34 | progressive multifocal and reverse geometry | -0.50∼-8.75 | 41% | 51% |
Lina H. Raffa, Malaysia, 2022 | RCT | 18 | 13–15 | + 3.00 | 9/10 | Proclear multifocal contact lenses | -2.00∼-6.00 | 63% | 66.6% |
Jenny Huang Jones, USA, 2022 | RCT | 36 | 7–11 | + 2.50D | 46/46 | Biofinity Multifocal “D” contact lenses | -0.75∼-5.00 | 43% | 50% |
Jeffrey J Walline, USA, 2013 | prospective, cohort study | 24 | 8–11 | + 2.00 | 32/32 | Proclear Multifocal “D” | -1.00∼-6.00 | 50% | 29% |
Padmaja Sankaridurg, China, 2011 | prospective, cohort study | 12 | 7–14 | + 2.00 | 40/40 | novel contact lenses | -0.75∼-3.50 | 34% | 33% |
Jaime Pauné, Spain, 2015 | prospective, longitudinal, nonrandomized study | 24 | 9–16 | + 6.00 | 19/21 | soft radial refractive gradient (SRRG) contact lenses | -0.75∼-7.00 | 43% | 27% |
Jianxia Fang, china, 2022 | RCT | 12 | 7–15 | + 6.00 | 22/24 | The BioThin (Bio Optic, Inc., Taiwan, China) MFSCLs | -1.00∼-8.00 | 26.8% | 37% |